Clinical Trial Update: Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated a combination of estramustine, docetaxel, and zoledronate in men with hormone-refractory prostate cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Estramustine (estramustine)
• Zoledronate (zoledronic acid)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Hormone-Refractory Prostate Cancer | Phase 2 | Status: COMPLETED